<DOC>
	<DOCNO>NCT02947854</DOCNO>
	<brief_summary>Fimaporfin ( TPCS2a ) photosensitiser drug develop PCI Biotech AS use novel Photochemical Internalisation ( PCI ) technology . PCI technology design enhance effect drug site-specific , light-directed manner use re-localise endocytosed molecule endosomes cytosol . This research study evaluate use PCI Technology combination adjuvant vaccine antigen safety induction immune response .</brief_summary>
	<brief_title>Study Assess Safety , Tolerability Immune Response Fimaporfin-induced Photochemical Internalisation Antigen/Adjuvant</brief_title>
	<detailed_description />
	<mesh_term>Poly ICLC</mesh_term>
	<mesh_term>Keyhole-limpet hemocyanin</mesh_term>
	<mesh_term>Photosensitizing Agents</mesh_term>
	<criteria>Inclusion Criteria 1 . Subjects ; 1.1. male females 1.2 . Caucasian 1.3. 18 55 year age , inclusive 2 . Subjects 2.1. body mass index ( BMI ) 18.0 32.0 kg/m2 , inclusive 2.2. body weight 50 100 kg , inclusive 3 . Subjects good health , determine ; 3.1. medical history , 3.2. physical examination , 3.3. vital sign assessment , 3.4 . 12lead electrocardiogram ( ECG ) 3.5. clinical laboratory evaluation ( congenital nonhaemolytic hyperbilirubinaemia acceptable ) 4 . Subjects give write informed consent participate study abide study restriction . Exclusion Criteria 1 . Male subject agree , whose partner childbearing potential agree , use appropriate contraception ( ie , condom spermicidal foam/gel/film/cream/suppository ) refrain donate sperm time first dose 3 month final dose administration . 1.1 . Male subject whose partner childbearing potential agree use additional acceptable method contraception . 2 . Female subject childbearing potential agree use 2 acceptable method contraception time screen 3 month final dose administration . 3 . Subjects negative result test human leukocyte antigen ( HLA ) A2 ( Parts B C ) . 4 . Subjects donate ; 4.1. blood 3 month prior screen , 4.2. plasma 7 day prior screen , 4.3. platelet 6 week prior screen . 5 . Subjects ; 5.1. consume 28 unit alcohol per week male 5.2. consume 21 unit alcohol per week female 5.3. significant history alcoholism drug/chemical abuse , determine Investigator Note : 1 unit alcohol equal ½ pint ( 285 mL ) beer lager , 1 glass ( 125 mL ) wine 25 mL spirit 6 . Subjects smoke 10 cigarette use equivalent tobacco per day . 7 . Subjects use follow within 7 day first dose ( use intermittent paracetamol ≤2 g/day acceptable ) , unless opinion Investigator medication interfere study procedure compromise safety : 7.1. nonprescribed systemic topical medication 7.2. herbal remedy 7.3. vitamin supplement 7.4. mineral supplement 8 . Subjects receive ; 8.1. prescribed systemic topical medication ( include steroid ) within 14 day first dose administration , unless opinion Investigator medication interfere study procedure compromise safety . 8.2. slowrelease medicinal formulation consider still active within 14 day first dose administration , unless opinion Investigator medication interfere study procedure compromise safety . 9 . Subjects receive vaccine within 3 month first dose administration . 10 . Subjects abnormality heart rate , blood pressure , temperature , respiration rate screen prior first dose opinion Investigator increase risk participate study . 11 . Subjects ; 11.1. positive urine drug abuse screen ( confirm repeat ) screen first admission . 11.2. positive alcohol breath test ( confirm repeat ) screen first admission . 12 . Subjects abnormality 12lead ECG screen prior first dose opinion Investigator increase risk participate study . 13 . Subjects pregnant , breastfeeding , lactate . 14 . Subjects still participate another clinical study ( eg , attend followup visit ) participate clinical study involve administration investigational drug ( new chemical entity ) past 3 month prior first dose administration . 15 . Subjects previously expose KLH antigen ( Parts B C ) . 16 . Subjects know previous exposure HVP E7 ( Parts B C ) . 17 . Subjects significant history drug allergy , determine Investigator . 18 . Subjects know allergy sensitivity Hiltonol and/or photosensitisers . 19 . Subjects clinically significant abnormal physical examination finding , determine Investigator . 20 . Subjects clinically significant medical history , determine Investigator . 21 . Subjects clinically significant allergic condition ( exclude nonactive hayfever ) , determine Investigator . 22 . Subjects porphyria hypersensitivity porphyrin . 23 . Subjects , history , clinically significant neurological , gastrointestinal , renal , hepatic , cardiovascular , psychiatric , respiratory , metabolic , endocrine , haematological , immunological major disorder , determine Investigator . 24 . Subjects clinically significant illness within 4 week first dose , determine Investigator . 25 . Subjects clinically significant abnormal laboratory safety finding screen prior first dose , determined Investigator ( 1 repeat assessment acceptable timepoint ) . 26 . Subjects Creactive protein value upper limit normal screen prior first dose ( 1 repeat assessment acceptable timepoint ) . 27 . Subjects ; 27.1. serum hepatitis , 27.2. carrier hepatitis B surface antigen ( HBsAg ) , 27.3. carrier hepatitis C antibody , 27.4. positive result test human immunodeficiency virus ( HIV ) antibody . 28 . Subjects tattoos , scar , mole opinion Investigator likely interfere dose study assessment potential dosing site ( upper arm abdomen ) . 29 . Subjects previously take part withdrawn study . 30 . Subjects , opinion Investigator , participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Vaccine</keyword>
	<keyword>Photochemical Internalisation</keyword>
	<keyword>Immune Response</keyword>
	<keyword>Peptide vaccine</keyword>
	<keyword>Anti cancer vaccine</keyword>
</DOC>